Study shows association between suPAR, non-AIDS comorbidities and all-cause mortality

Sun Oct 01 2017

“Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection” published in The Journal of Infectious Diseases

Persistent inflammation and immune activation have been associated with non-AIDS comorbidity and mortality in human immunodeficiency virus (HIV) infection. This study aimed to investigate the potential association between soluble urokinase plasminogen activator receptor (suPAR) and incident non-AIDS comorbidity and all-cause mortality in a well-treated HIV-infected population.

The study showed an independent association between a high suPAR level at baseline and increased hazard rates for both non-AIDS comorbidities (cardiovascular disease, chronic kidney disease, chronic lung disease, liver disease, and cancer) and all-cause mortality.

Read the full article here

To find out more about suPAR and infectious diseases, click here

+800

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates